Gorde:
| Egile Nagusiak: | , , |
|---|---|
| Formatua: | Recurso digital |
| Hizkuntza: | ingelesa |
| Argitaratua: |
Zenodo
2026
|
| Gaiak: | |
| Sarrera elektronikoa: | https://doi.org/10.5281/zenodo.20230267 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|
Aurkibidea:
- <p><strong>Episode summary:</strong> Most people think vaccine history is just Jenner, a gap, then polio, and then we figured it out. The real story is far more interesting. This episode traces five distinct platform shifts in vaccine technology — from whole-pathogen vaccines to recombinant proteins, conjugate vaccines, and the new genetic era of mRNA and viral vectors. We explore the bottlenecks that stalled progress for nearly a century, the accidental discoveries that broke them open, and what's actually in the pipeline today: universal flu vaccines targeting the stalk instead of the head, personalized cancer vaccines made from a patient's own tumor mutations, and needle-free delivery systems. The technology is not in maintenance mode — it's accelerating.</p> <h3>Show Notes</h3> <p>The history of vaccine technology is not a single linear progression but a series of distinct platform shifts, each built on a fundamental scientific advance that unlocked new possibilities. The story begins with variolation in China and India by at least the 1500s — deliberately infecting people with mild smallpox to protect against severe disease. Edward Jenner's 1796 breakthrough introduced a different principle: using a related but milder pathogen (cowpox) to provoke cross-protection. But without germ theory or an understanding of the immune system, no new vaccines were developed for nearly a century.</p> <p>Louis Pasteur broke the bottleneck in the 1880s through accidental attenuation — leaving a cholera culture out over the summer and discovering it still provoked immunity without causing severe disease. The next major platform shift came in the 1940s and 1950s with cell culture techniques that allowed viruses to be grown in non-nervous tissue, unlocking polio, measles, mumps, and rubella vaccines. The recombinant era began with hepatitis B vaccine in 1986, using genetic engineering to produce antigens in yeast. Conjugate vaccines then solved the problem of polysaccharide-encapsulated bacteria like Hib. The current genetic platform — mRNA and viral vectors — delivers instructions for antigens rather than the antigens themselves, enabling rapid development and new applications like personalized cancer vaccines targeting neoantigens unique to a patient's tumor.</p> <p>Listen online: <a href="https://myweirdprompts.com/episode/vaccine-platform-shifts-history">https://myweirdprompts.com/episode/vaccine-platform-shifts-history</a></p>